These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26099344)

  • 21. Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production.
    Tawfik DS; Cowan KR; Walsh AM; Hamilton WS; Goldman FD
    Pediatr Allergy Immunol; 2012 Feb; 23(1):88-95. PubMed ID: 21265884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.
    Siragam V; Crow AR; Brinc D; Song S; Freedman J; Lazarus AH
    Nat Med; 2006 Jun; 12(6):688-92. PubMed ID: 16715090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner.
    Lee SY; Jung YO; Ryu JG; Kang CM; Kim EK; Son HJ; Yang EJ; Ju JH; Kang YS; Park SH; Kim HY; Cho ML
    Arthritis Rheumatol; 2014 Jul; 66(7):1768-78. PubMed ID: 24644005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease.
    Lau AC; Duong TT; Ito S; Yeung RS
    Arthritis Rheum; 2009 Jul; 60(7):2131-41. PubMed ID: 19565485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
    Khan S; Doré PC; Sewell WA
    Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907
    [No Abstract]   [Full Text] [Related]  

  • 26. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
    Pagnini I; Marino A; Simonini G; Cimaz R
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S170. PubMed ID: 22410254
    [No Abstract]   [Full Text] [Related]  

  • 27. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease.
    Doi M; Takeda T; Sakurai Y; Kato J; Hayashi T; Fukuda K; Takase T; Shima M
    J Investig Allergol Clin Immunol; 2010; 20(5):413-8. PubMed ID: 20945608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease.
    Makata H; Ichiyama T; Uchi R; Takekawa T; Matsubara T; Furukawa S
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Aug; 373(5):325-32. PubMed ID: 16896803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of intravenous immunoglobulin on plasma interleukin-10 levels in Kawasaki disease.
    Noh GW; Lee WG; Lee W; Lee K
    Immunol Lett; 1998 May; 62(1):19-24. PubMed ID: 9672143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production.
    Tjon AS; van Gent R; Jaadar H; Martin van Hagen P; Mancham S; van der Laan LJ; te Boekhorst PA; Metselaar HJ; Kwekkeboom J
    J Immunol; 2014 Jun; 192(12):5625-34. PubMed ID: 24808368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy.
    Leucht S; Uttenreuther-Fischer MM; Gaedicke G; Fischer P
    Clin Immunol; 2001 Apr; 99(1):18-29. PubMed ID: 11286538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease.
    Kuo HC; Hsu YW; Wu MS; Woon PY; Wong HS; Tsai LJ; Lin RK; Klahan S; Hsieh KS; Chang WC
    Mediators Inflamm; 2015; 2015():564625. PubMed ID: 26089602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and immunological biomarkers to predict IVIg response.
    Galeotti C; Kaveri SV; Bayry J
    Trends Mol Med; 2015 Mar; 21(3):145-7. PubMed ID: 25680699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
    Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
    Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of dendritic cells and regulatory T cells by naturally occurring antibodies.
    Kwekkeboom J
    Adv Exp Med Biol; 2012; 750():133-44. PubMed ID: 22903671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC; Aronoff SC
    Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells.
    Massoud AH; Yona M; Xue D; Chouiali F; Alturaihi H; Ablona A; Mourad W; Piccirillo CA; Mazer BD
    J Allergy Clin Immunol; 2014 Mar; 133(3):853-63.e5. PubMed ID: 24210883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease.
    Sakurai Y; Takatsuka H; Onaka M; Takada M; Nishino M
    Int Arch Allergy Immunol; 2014; 165(2):111-8. PubMed ID: 25401215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin.
    Leung DY
    Clin Exp Immunol; 1996 May; 104 Suppl 1():49-54. PubMed ID: 8625544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.